Schedule 13D ownership disclosure
X4 Pharmaceuticals Inc
Common Stock, par value $0.001 per share · CUSIP: 98420X202
Event date: 2025-08-11
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Bain Capital Life Sciences Fund, L.P.Reported CIK 0001687968
Shares: 2,436,526 · Class: 9.99%
- Bain Capital Life Sciences Fund II, L.P.Reported CIK 0001773187
Shares: 2,436,526 · Class: 9.99%
- BCIP Life Sciences Associates, LPReported CIK 0001702921
Shares: 2,436,526 · Class: 9.99%
- BCLS II Investco, LPReported CIK 0001818893
Shares: 2,436,526 · Class: 9.99%
- BCLS I Investco, LP
Shares: 2,436,526 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-108341
- Form type
- SCHEDULE 13D
- Filer
- Bain Capital Life Sciences Fund, L.P.
- CIK
- CIK 1687968
- Filed
- Aug 13, 2025
- Reporting period
- Aug 11, 2025
- Description
- Schedule 13D beneficial ownership